Literature DB >> 7904244

Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors.

E Meller1, K Bohmaker, M Goldstein, D A Basham.   

Abstract

The activation constants (KA; dose required to occupy 50% of receptors) for reversal of gamma-butyrolactone (GBL)-induced elevation of striatal L-3,4-dihydroxyphenylalanine (L-DOPA) levels via stimulation of presynaptic dopamine receptors were determined for apomorphine and two dopamine D3 receptor-selective agonists, quinpirole and LY163502 (quinelorane). The KA values correlated significantly with the affinities (Ki) of the agonists for the D3 (r = 0.999, P < 0.05) but not the D2 (r = -0.13) receptor, suggesting that striatal synthesis-inhibiting autoreceptors are of the D3 rather than the D2 subtype.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7904244     DOI： 10.1016/0014-2999(93)90674-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  19 in total

1.  Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

Authors:  M C Coldwell; I Boyfield; A M Brown; G Stemp; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial self-stimulation in the rat.

Authors:  T Kling-Petersen; E Ljung; L Wollter; K Svensson
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo.

Authors:  J M Tepper; B C Sun; L P Martin; I Creese
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

4.  Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression.

Authors:  Neil M Richtand; Yanhong Liu; Rebecca Ahlbrand; Juliana R Sullivan; Amy Hauck Newman; Robert K McNamara
Journal:  Synapse       Date:  2010-08       Impact factor: 2.562

5.  Upregulation of (+)-7-hydroxy-N,N-di-n-[3H]propyl-2-aminotetralin binding following intracerebroventricular administration of a nitric oxide generator.

Authors:  D R Wallace; R M Booze
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

6.  Repeated 7-OH-DPAT treatments: behavioral sensitization, dopamine synthesis and subsequent sensitivity to apomorphine and cocaine.

Authors:  B A Mattingly; S E Fields; M S Langfels; J K Rowlett; P M Robinet; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

Review 7.  Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.

Authors:  T E Koeltzow; M Xu; D C Cooper; X T Hu; S Tonegawa; M E Wolf; F J White
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

8.  Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion.

Authors:  Minoru Narita; Keisuke Mizuo; Hirokazu Mizoguchi; Mamoru Sakata; Michiko Narita; Leon F Tseng; Tsutomu Suzuki
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

9.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

10.  Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour.

Authors:  N Waters; L Löfberg; S Haadsma-Svensson; K Svensson; C Sonesson; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.